EPHA participated in an online consultation and submitted comments to the WHO Europe on their recently launched multi-stakeholder Access to Novel Medicines Platform. The platform follows from the WHO Europe Oslo Medicines Initiative to which EPHA...
The transferable exclusivity voucher is a costly, complex and untested incentive for new antibiotics. It does not address access to new and old antibiotics, and it does not help with stewardship. We are worried that the European Commission plans to include the voucher...
To the EMA Executive DirectorTo the members of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)Cc: European Commission Brussels, 24 January 2023 Dear Chair and members of the MSSG, We are writing to you because we believe that the...
While the COVID-19 pandemic has brought access and affordability of medicines to the spotlight, it has also underscored the need for more balance, transparency, and accountability in the pharmaceutical sector. The 2022 Access to Medicines Forum coincides with the...
More than 32 million adults and 170,000 children live with a form of diabetes in the EU. Although 14 types of diabetes have been identified so far, the most common are Type 1 and Type 2. Most cases of Type 2 Diabetes are preventable. Yet, Type 1 and other forms are...